RB1 and acute pancreatitis: Our research provides further evidence into clinical applicability that Rb1 could be recommended as a therapeutic agent for ED in diabetes and provides a guideline for clinical studies evaluating the importance of managing vascular function in patients with hyperglycemia and ED, including in patients with acute pancreatitis.